Axovant Sciences
CompanyBermuda
Axovant Sciences develops one asset, in phase 3, discontinued (intepirdine in Alzheimer's disease). Mostly small molecule acting on HTR6; based in Bermuda.
- 1
- Asset
- Furthest stage
- Phase 3, discontinued
- 5
- Trials
- 1
- Signal
Pipeline
1Blocks serotonin 5-HT6 receptors to enhance neurotransmission involved in cognition.
Phase 3, discontinued, Small molecule, HTR6, Alzheimer's disease, dementia with Lewy bodies (Phase 2)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials5
- Signals1
- Similar companies6